Archives

  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2018-07

    • 2025-09-27

    5-(N,N-dimethyl)-Amiloride: A Next-Generation NHE1 Inhibitor for Cardiovascular and Cellular Research

    Introduction

    Intracellular ion homeostasis is fundamental to cell viability, signaling, and adaptation to stress. Among the molecular players orchestrating this equilibrium, the Na+/H+ exchanger (NHE) family has emerged as a central regulator of intracellular pH and sodium ion transport. Dysregulation of NHE activity is implicated in cardiovascular disease, ischemia-reperfusion injury, and metabolic dysfunction. 5-(N,N-dimethyl)-Amiloride (hydrochloride) (DMA, SKU: C3505) stands out as a powerful, selective NHE inhibitor, offering researchers a precise tool for dissecting Na+/H+ exchanger signaling pathways and their clinical implications.

    The Na+/H+ Exchanger: Roles in Physiology and Disease

    Isoform Diversity and Functional Significance

    The NHE family comprises several isoforms (NHE1–NHE9), each exhibiting tissue-specific expression and regulatory mechanisms. NHE1, the predominant isoform in cardiac myocytes and vascular endothelial cells, is essential for maintaining intracellular pH (pHi), cell volume, and sodium balance. NHE2 and NHE3 also contribute to sodium reabsorption and pH regulation, particularly in epithelial tissues.

    Pathological Activation and Consequences

    Aberrant activation of NHE1 is linked to pathological sodium and proton fluxes, exacerbating cellular injury under ischemic conditions and contributing to cardiac contractile dysfunction. In sepsis and systemic inflammation, endothelial NHE activity influences barrier permeability, intersecting with cytoskeletal regulators such as moesin—a key finding in recent biomarker studies (Chen et al., 2021).

    Mechanism of Action of 5-(N,N-dimethyl)-Amiloride (hydrochloride)

    Potency and Selectivity

    DMA is a crystalline solid derivative of amiloride, structurally optimized for enhanced potency against NHE isoforms. It exhibits Ki values of 0.02 μM for NHE1, 0.25 μM for NHE2, and 14 μM for NHE3, while exerting minimal inhibitory effects on NHE4, NHE5, and NHE7. This selectivity profile enables targeted interrogation of NHE1-mediated processes without off-target perturbation.

    Molecular Inhibition and Cellular Impact

    DMA functions as a competitive inhibitor, blocking the Na+/H+ exchange site and preventing proton extrusion and sodium uptake. This mechanism impairs the cell’s ability to correct intracellular acidification, thereby altering pHi regulation and sodium homeostasis. In cardiac tissue, DMA-mediated NHE1 blockade has been shown to normalize sodium levels, reduce contractile dysfunction, and protect against ischemia-reperfusion injury—a crucial advance for cardiovascular disease research.

    Broader Effects on Ion Transport and Metabolism

    Beyond NHE inhibition, DMA suppresses ouabain-sensitive ATP hydrolysis and sodium-potassium ATPase activity in rat liver plasma membranes, and reduces alanine uptake in hepatocytes. These findings suggest that DMA’s influence extends to multiple ion transporters and metabolic pathways, expanding its utility across cell biology and metabolism studies.

    Integrating 5-(N,N-dimethyl)-Amiloride into Advanced Research Paradigms

    Cardiovascular Disease and Ischemia-Reperfusion Injury Protection

    The role of NHE1 in ischemic cardiac injury has been a focal point of translational research. DMA’s ability to mitigate sodium overload and stabilize contractile function positions it as a valuable tool in modeling and potentially intervening in myocardial infarction, heart failure, and arrhythmic events. Crucially, DMA’s specificity allows for dissecting the distinct contributions of NHE1 versus other isoforms in these pathologies.

    Endothelial Dysfunction, Sepsis, and Moesin Signaling

    Recent work by Chen et al. (2021) identified moesin (MSN) as a biomarker and effector of endothelial injury in sepsis, highlighting the interplay between cytoskeletal remodeling and vascular permeability. NHE1 activity participates in this axis by modulating cell volume and pHi, influencing cytoskeletal dynamics. Using DMA to inhibit NHE1 in endothelial cell models enables precise dissection of how ionic fluxes govern MSN-mediated barrier function, immune signaling, and organ failure in sepsis. This approach complements earlier studies focused on MSN without targeted NHE inhibition, offering a new dimension to endothelial research.

    Intracellular pH Regulation and Na+/H+ Exchanger Signaling Pathways

    DMA’s high solubility (up to 30 mg/mL in DMSO or DMF) and robust inhibition profile make it ideal for live-cell imaging, electrophysiology, and metabolic flux analyses aimed at unraveling Na+/H+ exchanger signaling pathways. Its ability to rapidly alter pHi and sodium gradients is particularly valuable for studies requiring acute, reversible modulation of ionic homeostasis.

    Comparative Analysis: 5-(N,N-dimethyl)-Amiloride Versus Alternative NHE Inhibitors

    Advantages Over Amiloride and Other Analogs

    While classic amiloride has been widely used as an NHE inhibitor, its low potency and lack of isoform selectivity limit its utility in advanced research applications. DMA’s nanomolar affinity for NHE1 and minimal cross-reactivity with other NHE isoforms or unrelated cation transporters represent a significant upgrade. This enables more precise dissection of NHE1-dependent processes and reduces confounding variables in complex systems, such as cardiac or endothelial tissues.

    Technical Considerations and Limitations

    DMA should be stored at -20°C and its solutions used promptly to maintain potency, as long-term storage is not recommended. As with all small molecule inhibitors, off-target effects should be considered and appropriate controls included. Nonetheless, its favorable pharmacological profile and specificity make it the leading choice for NHE1-focused investigation.

    Expanding the Frontiers: Unique Research Applications of 5-(N,N-dimethyl)-Amiloride

    Modeling Cardiac Contractile Dysfunction and Arrhythmogenesis

    DMA enables the creation of in vitro and ex vivo models of cardiac contractile dysfunction by selectively perturbing NHE1. This facilitates the study of downstream events, such as calcium handling, mitochondrial stress, and arrhythmogenesis, providing mechanistic insight and a testing ground for therapeutic interventions.

    Dissecting Endothelial Barrier Function in Sepsis and Inflammation

    Building on the findings of Chen et al. (2021), DMA can be used to parse the relative contributions of NHE1 and moesin signaling in regulating endothelial permeability, leukocyte transmigration, and cytokine release. This is especially relevant as new biomarkers and therapeutic targets are sought for sepsis management.

    Exploring Sodium Ion Transport and Metabolic Regulation

    DMA’s impact on both sodium transporters and amino acid uptake opens avenues for research into the metabolic consequences of ion flux modulation, with implications for hepatocyte biology, cell energetics, and metabolic syndrome models.

    How This Article Extends the Existing Knowledge Base

    While many existing resources provide technical protocols or basic introductions to NHE inhibitors, this article offers a distinct, integrative perspective by:

    • Linking the function of 5-(N,N-dimethyl)-Amiloride (hydrochloride) directly to cutting-edge research on endothelial biomarkers and cytoskeletal signaling (as elucidated in Chen et al., 2021), rather than focusing solely on classic pH regulation.
    • Highlighting advanced applications in cardiovascular disease, sepsis, and metabolic regulation, which are often only briefly mentioned elsewhere.
    • Providing a comparative analysis of DMA versus traditional NHE inhibitors, offering researchers guidance on selecting the optimal tool for specific applications.

    This approach builds upon the foundational knowledge available in standard protocols, but goes further by integrating recent biomarker discoveries and offering nuanced application strategies for modern cell biology and disease modeling.

    Conclusion and Future Outlook

    5-(N,N-dimethyl)-Amiloride (hydrochloride) represents a next-generation NHE1 inhibitor that enables high-precision research into intracellular pH regulation, sodium ion transport, and the molecular underpinnings of cardiovascular and inflammatory diseases. By bridging advances in ion transport biology with modern biomarker research—such as the pivotal role of moesin in endothelial injury—DMA empowers researchers to unravel complex pathophysiological processes and develop novel therapeutic strategies. Future studies leveraging DMA are poised to deepen our understanding of Na+/H+ exchanger signaling pathways and their intersections with cytoskeletal dynamics, metabolic control, and organ protection in health and disease.